<SEC-DOCUMENT>0001144204-13-055334.txt : 20140423
<SEC-HEADER>0001144204-13-055334.hdr.sgml : 20140423
<ACCEPTANCE-DATETIME>20131015214844
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001144204-13-055334
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20131015

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Ruthigen, Inc.
		CENTRAL INDEX KEY:			0001574235
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				461821392
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		2455 BENNETT VALLEY RD. SUITE C116
		CITY:			SANTA ROSA
		STATE:			CA
		ZIP:			95404
		BUSINESS PHONE:		(707) 525-9900

	MAIL ADDRESS:	
		STREET 1:		2455 BENNETT VALLEY RD. SUITE C116
		CITY:			SANTA ROSA
		STATE:			CA
		ZIP:			95404
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 65%; padding-right: 0; padding-left: 0; text-indent: 0">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><img src="image_001.jpg" alt="Description: Mintz Levin only BW 2007" style="height: 36px; width: 218px"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&nbsp;</b></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in; text-align: left"><b>Linda Rockett </b>| 617 348
        4888 | lrockett@mintz.com</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P></td>
    <TD STYLE="width: 35%; padding-right: 0; padding-left: 0; text-indent: 0">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">One Financial Center</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Boston, MA 02111</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">617-542-6000</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">617-542-2241 fax</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">www.mintz.com</P></td></tr>
</table>


<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">October 15, 2013</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Via EDGAR and by Federal Express</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">United States Securities and Exchange Commission</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Division of Corporation Finance</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">100 F Street, N.E.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mail Stop 3561</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Attention: Jeffrey Riedler, Assistant Director</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; padding: 0; text-indent: 0"><B>Re:</B></TD>
    <TD STYLE="width: 95%; padding: 0; text-indent: 0"><B>Ruthigen, Inc.</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><B>Registration Statement on Form S-1 </B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><B>Filed August 8, 2013</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><B>File No. 333-190476</B></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are submitting this letter on behalf
of Ruthigen, Inc. (the &ldquo;<B>Company</B>&rdquo;) in response to comments from the staff (the &ldquo;<B>Staff</B>&rdquo;) of
the Securities and Exchange Commission (the &ldquo;<B>Commission</B>&rdquo;) received by letter dated August 23, 2013 (the &ldquo;<B>Comment
Letter</B>&rdquo;) from Jeffrey P. Riedler, Assistant Director, to Hojabr Alimi, the Company&rsquo;s Chief Executive Officer, relating
to the above-referenced registration statement on Form S-1 of the Company filed with the Commission on August 8, 2013 (the &ldquo;<B>Initial
Public Filing</B>&rdquo;). In conjunction with this letter, the Company is filing Amendment No. 1 to the registration statement
(&ldquo;<B>Amendment No. 1</B>&rdquo; and, as amended, the &ldquo;<B>Registration Statement</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">For convenient reference, we have set forth
below in italics each of the Staff&rsquo;s comments set forth in the Comment Letter and have keyed the Company&rsquo;s responses
to the numbering of the comments and the headings used in the Comment Letter. All of the responses are based on information provided
to Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. by representatives of the Company. Where appropriate, the Company has responded
to the Staff&rsquo;s comments by making changes to the disclosure in the Registration Statement as set forth in Amendment No. 1.
Page numbers referred to in the responses reference the applicable pages of Amendment No. 1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are providing by overnight delivery to
Daniel Greenspan of the Staff five courtesy copies of this letter and Amendment No. 1 that have been marked to show changes from
the filing of the Initial Public Filing filed on August 8, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Mintz, Levin, Cohn, Ferris, Glovsky and
Popeo, P.C.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Boston
| London | Los Angeles | New York | San Diego | San Francisco | Stamford | Washington</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Mintz, Levin, Cohn, Ferris, Glovsky and Popeo,
P.C.</B></P>

<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">October 15, 2013</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page 2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD><I>Please revise your financial statements and MD&amp;A with updated interim financial information through the period ended
June 30, 2013.</I></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.15in 0pt 0.5in"><B>Response: </B>The Company has revised the
Registration Statement throughout to include updated interim financial information for the period ended June 30, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.15in 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD><FONT STYLE="color: black"><I>We acknowledge your response to comment 6 and are uncertain why the fact that all direct or indirect
product related costs for RUT58-60 are included in your historical financial statements is determinative as to why carve-out financial
statements from Oculus are not necessary. With a view toward telling us more about the development history of RUT58-60, please
revise your disclosure in Business to provide a chronology of the activities related to the development of RUT58-60. At a minimum,
please disclose:</I></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 45pt"></TD><TD STYLE="width: 19.8pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><I>When Oculus conceived of RUT58-60;</I></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 45pt"></TD><TD STYLE="width: 19.8pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><I>The nature and timing of discovery activities;</I></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 45pt"></TD><TD STYLE="width: 19.8pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><I>The nature and timing of formulation activities;</I></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 45pt"></TD><TD STYLE="width: 19.8pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-right: 0.7in"><I>The nature and timing of other pre-clinical activities including in vitro and toxicology studies;</I></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 45pt"></TD><TD STYLE="width: 19.8pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-right: 0.15in"><I>The number of predecessor formulations and when each was founded that form the basis for the
current formulation of RUT58-60;</I></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 45pt"></TD><TD STYLE="width: 19.8pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><I>When the new, unique hypochlorous acid-based formulations that were disclosed to Oculus&rsquo; intellectual property counsel
in December 2012 were founded and how they relate to the formulations in the preceding bullet;</I></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 45pt"></TD><TD STYLE="width: 19.8pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-right: 0.25in"><I>The costs in terms of dollars and/or manpower associated with the discovery and formulation
activities, separating the activities untaken by Oculus from those you undertook.</I></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>In your response, separately tell us whether Oculus
sponsored the initial clinical trials conducted by physicians in Mexico that demonstrated the faster tissue healing associated
with hypochlorous acid products as disclosed on page 3. In addition tell us what information the Oculus Board of Directors reviewed
when, in November 2012, it directed Oculus management to explore the idea of creating a wholly-owned subsidiary within which to
pursue the development of RUT58-60.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>Response</B>: In addition to Regulation S-X, the
Company has reviewed and considered the SEC&rsquo;s guidance on the issue of historical and carve-out financial statements set
forth in SEC SAB Topic 1.B, the remarks by Leslie Overton, SEC Division of Corporation Finance, at the 2001 AICPA Annual National
Conference on Current SEC Developments, and SEC SAB Topic 5.Z and, in light of such guidance, the Company has revised its audited
financial statements that are included in the Registration Statement to reflect the activities of Ruthigen (carve-out activities)
from Oculus for the period beginning on October 20, 2011 (&ldquo;Inception&rdquo;), which is the date that the operations associated
with Ruthigen commenced. Accordingly, the revised Registration Statement now includes audited financial statements that capture
the activities of Ruthigen for the year ended March 31, 2013 and for the period from Inception to March 31, 2012, plus unaudited
interim financial statements for the three months ended June 30, 2013 and 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Mintz, Levin, Cohn, Ferris, Glovsky and Popeo,
P.C.</B></P>

<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">October 15, 2013</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page 3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The Company has revised the disclosures through the
Registration Statement to reflect these operations and has included a new subsection entitled &ldquo;Development History of RUT58-60&rdquo;
on page 54 of the &ldquo;Business&rdquo; section that describes the discovery, formulation and development <FONT STYLE="color: black">activities
of Ruthigen, which commenced prior to the formal incorporation of Ruthigen as a separate legal entity, that led to RUT58-60 as
the first target in a new class of products being pursued by Ruthigen</FONT>. Other than as set forth below, these new disclosures
address, among other things, those items in the bullet points and the November 2012 back up request identified by the Staff in
this comment 2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Due to the significant costs associated with preclinical
activities, including animal, in vitro and toxicology studies, no preclinical studies were conducted for RUT58-60 prior to the
Company&rsquo;s formal incorporation on January 18, 2013; all preclinical studies have been conducted since that time. The disclosure
under &ldquo;Select Pathogen Activity of RUT58-60&rdquo; in the &ldquo;Business&rdquo; section describes the results of certain
of the Company&rsquo;s preclinical studies for RUT58-60.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The Company has revised the Registration Statement
on pages 3 and 46 to remove the potentially confusing reference to clinical trials conducted in Mexico and in lieu thereof, the
Company has revised the disclosure to more generally refer to peer-reviewed journals that have published studies demonstrating
faster tissue healing times with hypochlorous acid based products. One example of such a study is the Landsman study, described
on page 52 of the Registration Statement, which was a clinical trial sponsored by Oculus, which used Oculus&rsquo; hypochlorous
acid based product (not RUT58-60).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">With respect to the clinical trials conducted by physicians
in Mexico, the Company has removed all references to such trials from the Registration Statement. We supplementally advise the
Staff that Oculus made certain payments to the physician conducting the clinical trial in Mexico and provided the physician with
Oculus&rsquo; hypochlorous acid based product to complete the trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.</TD><TD><I>We note that you are requesting confidential treatment for portions of Exhibit 10.4. Please be advised that we will review
your request for confidential treatment once it is received and will provide any comments under separate cover. We will not be
able to process any request for acceleration of the effective date of the pending registration statement until any such confidential
treatment request is resolved.</I></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>Response</B>: The Company acknowledges the Staff&rsquo;s
comment. Oculus, on behalf of the Company, filed a joint Application for Confidential Treatment with the Secretary of the Commission
on August 8, 2013 for portions of Exhibit 10.4 of the Company&rsquo;s Registration Statement and Exhibit 10.1 to Oculus&rsquo;
Current Report on Form 8-K originally filed with the Commission on June 7, 2013. On August 23, 2013, the Company delivered separately
to the Staff a copy of the joint Application for Confidential Treatment, dated August 8, 2013, which was submitted to the Secretary
of the Commission by Oculus. On September 11, 2013, Oculus, on behalf of itself and the Company, received a comment from the Staff
with respect to certain of the initially proposed redactions set forth in the Company&rsquo;s Exhibit 10.4 to the Registration
Statement and Exhibit 10.1 to Oculus&rsquo; Current Report on Form 8-K originally filed with the Commission on June 7, 2013. In
response to the comment, on September 24, 2013, Oculus filed an Amendment No. 1 to its Current Report on Form 8-K originally filed
with the Commission on June 7, 2013 to provide certain previously omitted portions of the license agreement, filed as Exhibit 10.1
to the Company&rsquo;s original Current Report on Form 8-K. Namely, as requested by the Commission, Oculus restored the amounts
of the milestone payments set forth in Section 7.1 of the license agreement. Accordingly, Exhibit 10.1 was re-filed with fewer
redactions and Oculus no longer requests confidential treatment for the amounts of the milestone payments set forth in Section
7.1 of the license agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"></P>

<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Mintz, Levin, Cohn, Ferris, Glovsky and Popeo,
P.C.</B></P>

<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">October 15, 2013</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page 4</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Similarly, the Company has also re-filed Exhibit 10.4
of its Registration Statement as part of Amendment No. 1, with fewer redactions to the license agreement filed as such Exhibit,
which are the same as those redactions in Oculus&rsquo; Exhibit 10.1. The joint Application for Confidential Treatment was also
revised to reflect this amended disclosure and was jointly re-submitted to the Commission by Oculus and the Company on September
24, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><U>SEC Comment Letter dated June 21, 2013</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">In addition, in response to comment 3 in the Staff&rsquo;s
comment letter to the Company dated June 21, 2013, we call the Staff&rsquo;s attention to the new graphics that appear on the front
cover of the prospectus included in the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><U>Other</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">In addition to revising the Registration Statement
to include responses to the Staff&rsquo;s comments above, the Company has revised the Registration Statement with respect to new
disclosures relating to, among other things, the reincorporation of the Company from Nevada to Delaware on September 25, 2013 and
the commensurate changes to the disclosures regarding Delaware corporate law, a 1-for-2.5 reverse stock split on September 25,
2013, the pricing information for the offering, and revised disclosures regarding Oculus&rsquo; secured debt facility, in light
of a new arrangement that Oculus has entered into with its lenders, the result of which is beneficial to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">*&#9;*&#9;*&#9;*&#9;*</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">When appropriate, the Company will provide
a written request for acceleration of the effective date of the Registration Statement and will include the requested &ldquo;Tandy&rdquo;
language therein. The Company and the underwriters are aware of their respective obligations under Rules 460 and 461 regarding
requesting acceleration of the effectiveness of the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Mintz, Levin, Cohn, Ferris, Glovsky and Popeo,
P.C.</B></P>

<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">October 15, 2013</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page 5</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We hope that the above responses and the
related revisions to the Registration Statement will be acceptable to the Staff. Please do not hesitate to contact me at 617-348-4888
or lrockett@mintz.com with any comments or questions regarding the Registration Statement and this letter. We thank you for your
time and attention.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 47%; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 53%; padding-right: 0; padding-left: 0; text-indent: 0">Sincerely,</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0; border-bottom: Black 1pt solid">/s/ Linda K. Rockett</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">Linda K. Rockett</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 3.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 3.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; padding-right: 0; padding-left: 0; text-align: justify; text-indent: 0">cc:</TD>
    <TD STYLE="width: 95%; padding-right: 0; padding-left: 0; text-align: justify; text-indent: 0"><I><U>Securities and Exchange Commission</U></I></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-indent: 0">Jeffrey Riedler, Assistant Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-indent: 0">Ibolya Ignat</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-indent: 0">Mark Brunhofer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-indent: 0">Amy Reischauer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-indent: 0">Daniel Greenspan</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-indent: 0"><I><U>Ruthigen, Inc.</U></I></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-indent: 0">Hojabr Alimi, Chief Executive Officer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-indent: 0">Sameer Harish, Chief Financial Officer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-indent: 0"><I><U>Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. </U></I></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-indent: 0">Ivan K. Blumenthal, Esq.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-indent: 0">Merav Gershtenman, Esq.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-indent: 0"><I>&nbsp;</I></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-indent: 0"><I><U>Sichenzia Ross Friedman Ference LLP</U></I></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-indent: 0">Jeffrey J. Fessler, Esq.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-indent: 0">Stephen A. Cohen, Esq.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-indent: 0"><I><U>Marcum LLP</U></I></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-indent: 0">Anthony Basile</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; text-indent: 0">Mitchell Watt</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 3.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MP``+"``D`-H!`1$`_\0`'P```04!`0$!`0$```````````$"`P0%!@<("0H+
M_\0`M1```@$#`P($`P4%!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$(
M(T*QP152T?`D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%56
M5UA96F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBI
MJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W
M^/GZ_]H`"`$!```_`/=-3OCIMA)="SNKLIC]S:H'D;G'`)&:Y[PG\1-%\8ZA
M>V&G)>175D,S174/ELO.",9Z@C!KK*S/$.O6/AC0KK6-19UM+907V#+')```
M[G)%9WA;QG:>+HA<:?INJ16;(6CNKFW$<<F#C"G))[]L<&NDHHHH!!Z'-%&0
M.]%%%</XD^*6C^$KH0:SINL6X9V2*4VH,<NT\E6#<]CZ\UT^C:L=8LC<_P!G
M7UB-V!'>Q"-R,`YQD\<]^>*T:***********^;8KF;P1XYB\>[W;3=2UF^L=
M0`'"+YQP?R&[ZQGUKZ11UD171@R,,JP.01ZUXW\9KJ7Q!9ZIHUM(R6.B68O]
M0=/XIFXAB/X%G/X5U_PYM8-3^$>A6TZN89+-58)(R'@]F4@CD=C7'_"W3OMW
MC;Q>E[?ZG=1:/J`AL8YK^9EB7?)U&[#?=7KG]:I>-8M=\&?$&WOO"<NH7-I9
MZ>;^]TZ:\DEC:/S-C[0Q/8@^V,CI7KGAGQ)IWBS0K?5]+F\RWF'*G[T;=T8=
MB/\`Z_0UP\_A:V'Q=M+!;O5!IDFE27CVHU&?89EE5=WW\XPXXZ<5KZ/\.K>%
M;NZU:]OY=0O;F6YG%KJ$\,*%V)"HJ,O`&!DC)Q7'^`M+76O'/C;3M0U'6)K3
M3+M8K2/^U;A?+4M(,9#Y/W1USTKH=4^'%ZNHZC+HVIW`AOM+>Q`OKR6<V[22
M)O=-Q)'[L-WZ@>M;,'@#0]/L566^UEDA3+RRZQ<+P!R3AP!^``KS_P`':9-X
MW\<76KV%_J]OX/TZ0101OJ$[_;I5ZL=S$[><D>F!W->W5XQ^T,,Z=X:S_P!!
M`_R%>SU@^,M.AU'PMJ`E>XC:"WDFB>"=XF1U0X.5(S]#Q[5P?PHT.'Q+\/;'
M5-6O]8N+R624/)_:MRN0KD#A7`Z`5M1?#PO_`&W:C6]2;3[H))I\HU&9IK28
M!U?YMW*YVG!)[@UD_!&\DDT[6=/U26ZDU_3KQH+QKBYDE++D[2`Q('(<<`=*
MWOBBK3^';:QM&G75[^[2UT]H9Y(BDC'YG.PC*J@9CG(XI=8\'6&G>`K^!+K4
MWN+:TDF6[:_F\TRK&?G)W^HSCI[5A_"'28=;^'$&HZI<ZA=W=\94GEEOYB2J
MRD`#YOE^Z.1@]>>:Y73_`!'K'PY\;ZO<7D]]?^#CJ)T^22>=IWM'"JZGYB3@
M"3'N`>X%>Y2)9ZUI>!)YUG=1@AX92N]3R"K*0?Q!K@O`&@QP>*?$TDU[J-S_
M`&=J)M[-+B^ED6*,QJV-I;!^_C)R>*](HKRGP[X=A\;?!.YT^3;OO;B\FA<_
MP2_:)"C?F!GV)JE\,_B(MC\-M3M];W_VCX:!@>%OOR+G;$@_VMW[O\!ZU>\0
M:'<:+\#_`!#)J)#:OJ$37FH/ZS.RDJ/91A1[+70_"5]_PK\/G&/]'(_)V%<U
M\)/^1W^(_P#V%O\`V>:NG8C_`(7.JGJ?#QX_[>!_C7&>(=)U#X2^(I?%GAR!
MI_#5VX_M738^D))_UB#L.?PZ=#QT^G:Q8Z_\3=(U33;A9[.X\/3M'(O_`%WB
MR#Z$=".QKOJ\E^%O_)3?B3_U_I_Z'+7K5>4?$36+WQ=XAA^''AZ8J\P$FL7:
M<BW@X)3ZG(R/=1W./2=&T>RT#1[72M.A$5I;1A(U]O4^I)R2>Y-7J\8_:%_Y
M!WAK_L('^0KV>LSQ'_R*^K?]>4W_`*`:\J^$&BZ_>_#2QFT_Q7/I\+23!(%L
M890A\QL\L,G)YZ]Z]%\!Z7?:+X-LM/U,?Z;$\WFMD'>3,[;^/[V=WXUPFOG_
M`(03XWZ;K@^32O$D?V.[/\*S#`5CZ?P'/^_76:</^$B^(=]JI^:QT)#I]IW!
MN7`:=Q_NC9'_`-]UN>*?^11UK_KPG_\`1;5R'P-_Y)+I/^_/_P"CGJWX9TZS
MU=_'6GW\"7%I<:U)'+&XR&'D0_K[]C7(Z3J5[\&O$2>'M:FDN/!]](3IU^_/
MV1B<E'/8>O\`WT/X@.U\$D-XA\:,I!5M64@CH0;>+FNSK*\07NJ66FLVD:2^
MI73Y58Q.D04XX9BY'&?3)KEOA9I_B#P[X9M/#VLZ(]O]F$K?;%N8I$<LY;&`
MVX'YCVQQUK,N?A:L_P`:(_$P0#2FB%U,FX8:Z4X4%?3H^?53ZUO_`!(MM;U;
MPM>Z)HVC->R7\)C,YN(XTAY'4,<DX]!6=\.X/$WACP7!HFI^&I3-81OY<D-W
M"RSYD)"C+#:<,>O'R]>0*S?A[HWBKP]XM\17NI>'62TUV\%P'CO(7-M\SG##
M=EN'_ASTZ5HSIXI7XFKX@C\,3/IT>G-I^P7D`D8F0/Y@!?&.`,$YKT&2-)X'
MBFC5XY%*NC@$$$<@CN*\T\)_#>3P7\3[O4-.!;0+NQD$:%^;:0R1DI@]0<9!
M]L'ID^C7UQ/:V<DUM9R7DJXVP1NJLW/8L0/?DUYAX%T?Q9H/C;Q%JFH>&V6T
MUVY64&.\A9K<!F/S#=SP_;/3O7>^*KG7;;0)SX;L$O-4?Y(5DD5%C)_C.XC(
M'IW.*X'X>Z+XC\%Z9<FZ\)SWVL7TS37M[_:$&93DX`RV<#.?J36WK^K>/=0T
MZ6PT?PJ;">Y7R_MTVHPG[.#P7"J<D@<C^O2NYMX?L]M%#O>3RT";W.6;`QDG
MN:\B^+/A[QAXW>QL]*\/^5#87#RK<SWD0\WLI50V0._.#77P^(O&BVR?:/`C
M-.`-_DZK!M)]1G'%830^-KZ;7M5U#PXPN+RS_L_3["*_B*P1D,6>1BP!)8CH
M,X7&*B^'=KXS\%>$XM$O/"9NO(D=XY8-0A&0QW8(8CG)/>NBLI_%VL^+;*6^
MTF31=%LXY)&0WD<KW4I&U58(3A0"S8]0/04?%'PM)XN\"WMC:Q%[^$BXLP"`
M?-7L"?4%A^-;'A/0QX<\+V&EES)-%'F>4G)DE8[I&)[Y8DU'XP;4W\.7EGI6
ME/?W%W!)``)DC6,LI`9BQ''/;)KF?ACI_B'PIX+30]4T"436:RR1R174++.6
M<L%'S94_,>O''6I/!,'B;3-<UPZIX=D@M=5U%KR.5+N%_)!4+AP&SG"C[N>M
M=;K^@:=XFT6XTG5(!-:SK@CH5/9E/8CL:Y/X5^#=0\$66M:9?2>=&U]OMKC/
F^MB\M0IQV(QC'MQQ7?T4444444444444444444444444445__]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
